Taro Pharmaceutical: 10% Projected Earnings Yield Is A Strong Calling Card (NYSE:TARO)
Based on the current long-term trend, shares look like they will test long-term support. We expect support to hold there based on the company´s strong earnings power and clean balance sheet.
Taro Pharmaceutical: 10% Projected Earnings Yield Is A Strong Calling Card (NYSE:TARO)
Based on the current long-term trend, shares look like they will test long-term support. We expect support to hold there based on the company´s strong earnings power and clean balance sheet.